

Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator,

8701 Morrisette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on September 7, 2026,

National Center for Natural Products Research, 806 Hathorn Road, 135 Coy Waller Lab, University, Mississippi 38677, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Marihuana	7360	I
Tetrahydrocannabinols	7370	I

The company plans to acquire new genetic materials with different cannabinoid profiles for research and manufacturing purposes. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Justin Wood,
Deputy Assistant Administrator.
 [FR Doc. 2026-21358 Filed 10-16-26; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1790]

Importer of Controlled Substances Application: DMS Pharmaceutical Group

AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.

SUMMARY: DMS Pharmaceutical Group has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 18, 2026. Such persons may also file a written request for a hearing on the application on or before November 18, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment

field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on September 4, 2026, DMS Pharmaceutical Group, 810 Busse Highway, Park Ridge, Illinois 60068, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Fentanyl	9801	II

The company plans to import the controlled substance for distribution to military combat units. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-

approved finished dosage forms for commercial sale.

Justin Wood,
Deputy Assistant Administrator.
 [FR Doc. 2026-21354 Filed 10-16-26; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1790]

Importer of Controlled Substances Application: Groff NA Hemplex LLC

AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.

SUMMARY: Groff NA Hemplex LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 18, 2026. Such persons may also file a written request for a hearing on the application on or before November 18, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All

requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on September 23, 2026, Groff NA Hemplex, LLC, 2218 South Queen Street, York, Pennsylvania 17402, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Marihuana Extract	7350	I
Marihuana	7360	I
Tetrahydrocannabinols ...	7370	I

The company plans to import listed controlled substances in bulk form to manufacture research grade material for clinical trial studies. Several types of Marihuana Extract compounds are listed under code 7350. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Justin Wood,
Deputy Assistant Administrator.
[FR Doc. 2026–21367 Filed 10–16–26; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Muhamad Aly Rifai, M.D.; Decision and Order

I. Introduction

On November 30, 2023, the Drug Enforcement Administration (DEA or Government) issued an Order to Show Cause (OSC) to Muhamad Aly Rifai, M.D. (Respondent). Request for Final Agency Action (RFAA), Exhibit (RFAAX) 3, at 1, 7. The OSC proposed the revocation of Respondent's DEA Certificate of Registration, No.

BR7552272, in Easton, Pennsylvania. *Id.* at 3. The OSC alleged that Respondent's registration should be revoked because his "continued registration is inconsistent with the public interest." *Id.* at 1 (citing 21 U.S.C. 823(g)(1)). The OSC also proposed the revocation of Respondent's registration, alleging that the "falsification of patient medical records to conceal the unlawful prescribing of controlled substances may be considered by the Agency as conduct that threatens the public health or safety and grounds to revoke or deny a DEA Registration." *Id.* at 3.

A. Procedural Background

On December 28, 2023, Respondent filed a timely hearing request with the Office of the Administrative Law Judges (ALJs). *Id.* at 2; see RFAAX 25, at 17–19. A hearing on the merits was initially scheduled for April 29, 2024. RFAAX 5, at 5. After some lengthy procedural exchanges between the parties and the ALJ,¹ the matter was terminated because the ALJ found that Respondent "desires delay, during which time he can continue to prescribe schedule II controlled substances despite very serious allegations against him." RFAAX 2, at 16. The ALJ then terminated the hearing proceedings on August 20, 2024, and concluded that the "Respondent, in fact, does *not* desire a hearing before this tribunal." RFAAX 2, at 16. The ALJ did not find that Respondent was in default. RFAAX 2.

Thereafter, on September 5, 2024, the Government submitted a request for final agency action arguing that the Administrator may enter a default final revoking Respondent's registration. RFAAX 25, at 1, 4. On July 8, 2025, the Administrator denied the Government's request to find Respondent in default because Respondent "continued to defend his case and contest the allegation on their merits." RFAAX 26, at 8; see RFAA, at 6. Instead, the Administrator found that the ALJ's Termination Order arose from her duties "to take all necessary action to avoid delay, and to maintain order." RFAAX 26, at 2 (citing 21 CFR 1316.52). The Administrator then returned the matter to the Government for further action, including an opportunity to file a new RFAA that contains substantial record evidence supporting the revocation of Respondent's registration. RFAAX 26, at 8–9.

On August 25, 2025, the Government submitted another RFAA and requested

¹ The lengthy procedural history in this matter is set forth fully in the ALJ's August 20, 2024, Order Vacating Stay and Terminating Proceedings. RFAAX 2, at 1–17.

that the Agency revoke Respondent's registration because his prescribing patterns were "outside the usual course of professional practice and not for a legitimate medical purpose" and Respondent falsified patient medical records. RFAA, at 18 (citing 21 CFR 1306.04(a) and multiple state laws).² The Government contended that these violations demonstrated that Respondent's continued registration is inconsistent with the public interest. RFAA, at 19 (citing 21 U.S.C. 824(a)(4), 823(g)(1)(B), (D)).³

After carefully reviewing the entire record and conducting the analysis as set forth in more detail below, the Agency grants the Government's RFAA and revokes Respondent's registration.

II. Law Applicable to Public Interest Determination

A. Legal Background on Public Interest Determinations

Congress enacted the Controlled Substances Act (CSA) "to conquer drug abuse and control the legitimate and illegitimate traffic in controlled substances." *Gonzales v. Raich*, 545 U.S. 1, 12 (2005). A particular concern of Congress was "the need to prevent the diversion of drugs from legitimate to illicit channels," and it "devised a closed regulatory system making it unlawful to manufacture, distribute, dispense, or possess any controlled substance except in a manner authorized by the CSA." *Id.* at 12–13.

The CSA's requirements under this closed regulatory system include that "[e]very person who dispenses, or who proposes to dispense, any controlled substance, shall obtain from the [DEA] a registration." 21 U.S.C. 822(a)(2); see also *Gonzales v. Raich*, 545 U.S. at 27–28. To protect the American people and ensure compliance with the CSA, Congress empowered the Agency⁴ to deny, suspend, or revoke a registration if it would be inconsistent with the public interest. 21 U.S.C. 823(g)(1); 21

² The Agency need not adjudicate the criminal violations alleged in the OSC/ISO. *Ruan v. United States*, 597 U.S. 450 (2022) (decided in the context of criminal proceedings).

³ The Government cited to 21 U.S.C. 823(f)(2), (4), which is not the current designation of the public interest factors. Effective December 2, 2022, the Medical Marijuana and Cannabidiol Research Expansion Act, Public Law 117–215, 136 Stat. 2257 (2022) (Marijuana Research Amendments or MRA), amended the Controlled Substances Act (CSA) and other statutes. Relevant to this matter, the MRA redesignated 21 U.S.C. 823(f), cited in the OSC, as 21 U.S.C. 823(g)(1). Accordingly, this Decision cites to the current designation, 21 U.S.C. 823(g)(1), and to the MRA-amended CSA throughout.

⁴ The CSA delegates this power to the Attorney General, who has delegated it to the Administrator of the DEA (the Agency) by 28 CFR 0.100.